Platelet inhibitor therapy: Current perspectives and emerging novel agents: Introduction
Antiplatelet therapy plays a key role in preventing atherothrombotic complications in patients with acute coronary syndromes and/or undergoing percutaneous coronary interventions. Despite such clinical benefit, currently available agents may present limitations. Several novel antiplatelet medications are currently under advanced clinical testing. Results from ongoing clinical studies will determine the efficacy and safety of these novel agents compared to those currently available.
Conflicts of Interest: Dominick J. Angiolillo, MD, PhD, FACC, FESC has declared the following conflicts of interest: Honoraria/Lectures: Bristol Myers Squibb (New York, NY); Sanofi-Aventis (Bridgewater, J); Eli Lilly and Company (Indianapolis, IN); Daiichi Sankyo, Inc (Parsippany, NJ). Honoraria/Advisory board: Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc.; The Medicines Company (Parsippany, NJ); Portola (San Francisco, CA); Novartis (East Hanover, NJ). Research Grants: GlaxoSmithKline (Brentford, London, United Kingdom); Otsuka (Tokyo, Japan). Eric R. Bates, MD, FACC has declared the following conflicts of interest: Honoraria/Lectures: Sanofi-Aventis; Hoffmann-La Roche (Nutley, NJ). Honoraria/Advisory board: Eli Lilly Co; The Medicines Company; Daiichi Sankyo, Inc.; Medicure Pharma (Winnipeg, Manitoba, Canada). Research Grants: Eli Lilly and Company.
PII: S0002-8703(08)00469-9
doi:10.1016/j.ahj.2008.06.002
© 2008 Mosby, Inc. All rights reserved.
